BEZ235

AssetSmall moleculeAlso BEZ235 plus everolimus (RAD001)

Dual PI3K and mTOR inhibitor targeting age-related immunosenescence

Stage: Phase 2
Modality: Small molecule
Target: mTOR signalling
Indications: 1
Trials: 641
Developers: 1

Indications

1

Respiratory tract infection
Phase 2ACTIVE_NOT_RECRUITINGNCT03373903clinicaltrials.gov7 Oct 2026

Targets and what it contains3
Owner and partners1
Trials641
Evidence for its targets2
Competitors12
Aging relevance2
Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 3 sources